News
The combination of once-weekly cagrilintide 2.4 mg and semaglutide 2.4 mg conferred greater weight loss at 68 weeks compared ...
1d
MedPage Today on MSNOnce-Weekly Basal Insulin Non-Inferior to Several Daily Options in Type 2 DiabetesA once-weekly basal insulin had similar safety and efficacy to a daily insulin option, a series of trials from the phase III ...
Diabetes pills could hit Australian shelves within years, offering an alternative to popular injectable treatments such as ...
Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX) American Diabetes Association (ADA) 85th Scientific Sessions Conference June 20, 2025 8:15 PM ET James Markmann - Corporate Participant Michael ...
Women who replaced their lunchtime diet beverage with water had greater weight loss and achieved diabetes remission compared ...
2d
MedPage Today on MSNNovel Oral GLP-1 Agent Cuts A1c, Weight in Early DiabetesAn investigational, oral small-molecule GLP-1 receptor agonist improved glycated hemoglobin levels in adults with early-stage ...
9h
Medpage Today on MSNCombo Semaglutide-Amylin Analogue Boosts Weight Loss Regardless of DiabetesCHICAGO -- Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with ...
Most in a small group of patients receiving a stem cell-based infusion no longer needed insulin, but the drug may not suit those with more manageable type 1 diabetes.
The first diabetes and obesity pill that is similar to Ozempic — but in tablet form — may actually outperform the popular ...
Endogenex today reported positive findings from studies of its endoscopic procedure aimed at transforming diabetes care.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results